MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MEK1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy (1). Mechanisms of clinical resistance to combined RAF/MEK in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wagle, Nikhil, Van Allen, Eliezer M., Treacy, Daniel J., Frederick, Dennie T., Cooper, Zachary A., Taylor-Weiner, Amaro, Rosenberg, Mara, Goetz, Eva M., Sullivan, Ryan J., Farlow, Deborah N., Friedrich, Dennis C., Anderka, Kristin, Perrin, Danielle, Johannessen, Cory M., McKenna, Aaron, Cibulskis, Kristian, Kryukov, Gregory, Hodis, Eran, Lawrence, Donald P., Fisher, Sheila, Getz, Gad, Gabriel, Stacey B., Carter, Scott L., Flaherty, Keith T., Wargo, Jennifer A., Garraway, Levi A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3947296/
https://ncbi.nlm.nih.gov/pubmed/24265154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0631
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares